A new four-year research project involving a consortium of government, non-profit and other large biopharma partners is aiming to create a set of measures that can be used in clinical trials to determine which ASD (autism spectrum disorder) treatments...
As the hype continues to hover around the promise of gene and cell therapies, the latest guidance from the FDA will help sponsors, CROs and investigators design early-phase clinical trials for the products, which may pose substantial risks to patients.
Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US operations.
Strategic partnerships were put on trial yesterday at PCT and with a number of alliances coming up for renewal, Pfizer, Novartis, Amgen and Baxter spoke about the issues affecting a sponsor-CRO relationship.
Oxford Genome Sciences (OGeS) has taken a step closer to shedding
its service provider skin and morphing into a pharma firm after
entering a new cancer collaboration with Amgen, one of the world's
largest biotech firms.